Issue navigation
Volume 110, Issue 6, June 2018
Solicited Editorial
Circulating Tumor Cells in Patients Receiving Neoadjuvant Chemotherapy: Refining the Paradigm of Prognosis and Treatment Individualization
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 543–544, https://doi.org/10.1093/jnci/djy065
Smoking Cessation Pharmacotherapy, Even Without Counseling, Remains a Cornerstone of Treatment
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 545–546, https://doi.org/10.1093/jnci/djx246
Using Metabolomics to Explore the Role of Postmenopausal Adiposity in Breast Cancer Risk
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 547–548, https://doi.org/10.1093/jnci/djx283
A New Gastric Cancer Among Us
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 549–550, https://doi.org/10.1093/jnci/djx279
Supplements to Help Prevent Neuropathy During Chemotherapy? A Cautionary Tale
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 551–552, https://doi.org/10.1093/jnci/djx294
Commentary
A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 553–559, https://doi.org/10.1093/jnci/djy064
Meta-Analysis
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 560–567, https://doi.org/10.1093/jnci/djy018
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 568–580, https://doi.org/10.1093/jnci/djx273
Articles
Effectiveness of Pharmaceutical Smoking Cessation Aids in a Nationally Representative Cohort of American Smokers
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 581–587, https://doi.org/10.1093/jnci/djx240
A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 588–597, https://doi.org/10.1093/jnci/djx244
Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 598–607, https://doi.org/10.1093/jnci/djx249
The Changing Face of Noncardia Gastric Cancer Incidence Among US Non-Hispanic Whites
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 608–615, https://doi.org/10.1093/jnci/djx262
Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 616–627, https://doi.org/10.1093/jnci/djx255
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 628–637, https://doi.org/10.1093/jnci/djx258
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 638–648, https://doi.org/10.1093/jnci/djx253
Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 649–660, https://doi.org/10.1093/jnci/djx235
Validation of the Symptom Screening in Pediatrics Tool in Children Receiving Cancer Treatments
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 661–668, https://doi.org/10.1093/jnci/djx250
Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715)
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 669–676, https://doi.org/10.1093/jnci/djx259
Brief Communication
Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Pages 677–681, https://doi.org/10.1093/jnci/djx271
Corrigendum
Corrigendum to “Reported Incidence and Survival of Fallopian Tube Carcinomas: A Population-Based Analysis From the North American Association of Central Cancer Registries”
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Page 682, https://doi.org/10.1093/jnci/djy078
Corrigendum to “Connective Tissue Growth Factor and its Role in Lung Adenocarcinoma Invasion and Metastasis”
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Page 683, https://doi.org/10.1093/jnci/djy062
Corrigendum to “Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer”
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Page 684, https://doi.org/10.1093/jnci/djy095
Corrigendum to “Investigation of the Relationship Between Radiation Dose and Gene Mutations and Fusions in Post-Chernobyl Thyroid Cancer”
JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, June 2018, Page 685, https://doi.org/10.1093/jnci/djy066
